The newest weight-loss drugs, Wegovy and Zepbound ... the FDA also added to Zepbound’s label that it can reduce the symptoms of obstructive sleep apnea. Other health benefits, including the ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Future growth could also be driven by Wegovy's approval ... of rising sales of Zepbound and diabetes therapy Mounjaro, also based on tirzepatide, saying it was seeing the benefit of an increased ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of years thanks to new technologies, former U.S. Treasury Secretary ...

This class of drugs, known as glucagon-like peptide-1 receptor agonists, or GLP-1s, also includes Wegovy and Zepbound ... behavioral health and cognitive benefits. Using a U.S. Department ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other ... and weight loss drug Zepbound because they haven't been ...

In addition to Wegovy, incretin mimetics FDA-approved for chronic weight management include Saxenda (liraglutide), also made by Novo Nordisk, and Zepbound (tirzepatide), produced by Fortune 500 ...